Repligen Corporation (NASDAQ:RGEN) – Analysts at First Analysis increased their FY2017 earnings estimates for Repligen Corporation in a research note issued on Wednesday. First Analysis analyst now anticipates that the biotechnology company will post earnings per share of $0.60 for the year, up from their prior forecast of $0.55. First Analysis has a “Equal Weight” rating and a $40.00 price objective on the stock. First Analysis also issued estimates for Repligen Corporation’s Q4 2017 earnings at $0.16 EPS and FY2018 earnings at $0.72 EPS.
Other equities analysts also recently issued reports about the company. BidaskClub downgraded Repligen Corporation from a “strong-buy” rating to a “buy” rating in a report on Wednesday, June 14th. Jefferies Group LLC restated a “hold” rating and set a $40.00 price target (up from $33.00) on shares of Repligen Corporation in a report on Wednesday, June 28th. William Blair began coverage on Repligen Corporation in a report on Friday, July 21st. They set an “outperform” rating for the company. Zacks Investment Research downgraded Repligen Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. Finally, Janney Montgomery Scott raised their price target on Repligen Corporation from $42.00 to $47.00 in a report on Friday, June 23rd. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $42.00.
WARNING: “Repligen Corporation (NASDAQ:RGEN) Expected to Earn FY2017 Earnings of $0.60 Per Share” was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.com-unik.info/2017/08/12/repligen-corporation-nasdaqrgen-expected-to-earn-fy2017-earnings-of-0-60-per-share.html.
Shares of Repligen Corporation (RGEN) opened at 41.18 on Friday. The firm’s 50-day moving average is $41.91 and its 200-day moving average is $36.63. Repligen Corporation has a 52 week low of $26.16 and a 52 week high of $46.81. The company has a market cap of $1.54 billion, a price-to-earnings ratio of 80.59 and a beta of 1.30.
Repligen Corporation (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 EPS for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.05. The business had revenue of $32.40 million during the quarter, compared to analyst estimates of $31.72 million. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. Repligen Corporation’s quarterly revenue was up 11.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.16 EPS.
Institutional investors have recently modified their holdings of the stock. US Bancorp DE increased its position in shares of Repligen Corporation by 1.2% in the second quarter. US Bancorp DE now owns 4,629 shares of the biotechnology company’s stock valued at $191,000 after buying an additional 54 shares during the last quarter. Pinebridge Investments L.P. increased its position in shares of Repligen Corporation by 1.7% in the second quarter. Pinebridge Investments L.P. now owns 4,491 shares of the biotechnology company’s stock valued at $186,000 after buying an additional 76 shares during the last quarter. State of Alaska Department of Revenue increased its position in shares of Repligen Corporation by 2.2% in the first quarter. State of Alaska Department of Revenue now owns 3,740 shares of the biotechnology company’s stock valued at $131,000 after buying an additional 80 shares during the last quarter. Arizona State Retirement System increased its position in shares of Repligen Corporation by 0.6% in the second quarter. Arizona State Retirement System now owns 17,726 shares of the biotechnology company’s stock valued at $735,000 after buying an additional 100 shares during the last quarter. Finally, NBW Capital LLC increased its position in shares of Repligen Corporation by 0.5% in the first quarter. NBW Capital LLC now owns 22,655 shares of the biotechnology company’s stock valued at $797,000 after buying an additional 118 shares during the last quarter. Hedge funds and other institutional investors own 99.02% of the company’s stock.
Repligen Corporation Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
What are top analysts saying about Repligen Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Repligen Corporation and related companies.